📢 What This Document Is

This is an 8-K filing—a report public companies use to announce major news to investors. Here, SAB Biotherapeutics (ticker: SABS) is sharing exciting new clinical trial data that was just presented at a major medical conference. Think of it as a detailed press release filed with the SEC.

👉 Why it matters: This isn't just a routine update. It provides the first deep look at how their drug works in patients, which is crucial for proving its value to both regulators and the market.

🧬 What The Company Does & The Disease

SAB Biotherapeutics is a clinical-stage biotech company. In simple terms, they use a unique technology (involving genetically engineered cattle) to create fully human antibodies to treat autoimmune diseases.

Their lead drug, SAB-142, is being developed for Type 1 Diabetes (T1D). T1D is an autoimmune disease where the body's own immune system mistakenly destroys the insulin-producing beta cells in the pancreas. SAB-142 aims to be a disease-modifying therapy—not just managing symptoms, but potentially slowing or stopping this destructive immune attack.

🔬 The Clinical Data: What They Found

The data comes from a small Phase 1 trial in adults with established T1D (diagnosed 28-40 months prior). The key findings are about the drug's biological effect (mechanism) and early signs of clinical benefit.

C-Peptide Preservation (The Key Biological Signal)

• What is C-peptide? It's a byproduct created when the body makes its own insulin. Its level is a direct measure of how well the patient's remaining beta cells are functioning.
• The Result: All 4 participants who received SAB-142 showed preserved C-peptide levels after 120 days. Even better, 3 of them were classified as "super responders," meaning their C-peptide levels actually increased above baseline.
• 👉 The Big Deal: In contrast, the one placebo participant who completed the study showed a decline in C-peptide, which is the expected progression of the disease. This suggests SAB-142 may be actively protecting beta cells.

Mechanism: Exhausting the "Bad" Immune Cells

• The trial showed SAB-142 induced T cell exhaustion. Think of it like tiring out the rogue immune cells (CD4+ Tconv cells) that are attacking the pancreas, making them less aggressive. The "super responders" showed an early and sustained increase in these "exhausted" T cells (marked by TIGIT⁺).

Glycemic Control (The Patient Impact Signal)

• Participants on SAB-142 saw their Time in Range (TIR)—the percentage of time their glucose levels were in a healthy zone—improve from 73% to 85%.
• Crucially, this improvement happened without needing more insulin injections. This hints that the preserved beta cells are doing more work.

🚀 What This Signals for SAB-142

This data is about proof of concept and differentiation.

1. Validates the Mechanism: It shows SAB-142 works as intended—inducing T cell exhaustion to protect beta cells. This aligns with data from an older, animal-derived drug (rabbit ATG).
2. Highlights a Safety Advantage: The company emphasizes they saw "sustained immunomodulation without immunodepletion." This is a fancy way of saying the drug calms the immune system without broadly depleting it, which could lead to fewer side effects like severe infections.
3. Supports the "Best-in-Class" Claim: The combination of efficacy signals and a potentially safer profile is what the company hopes will make SAB-142 a superior, long-term treatment option.

🗓️ What's Next: The Path Forward

The immediate future is all about the pivotal Phase 2b SAFEGUARD trial. This is the larger study designed to gather the definitive efficacy and safety data needed for eventual drug approval.

• Status: The trial is actively enrolling new-onset T1D patients worldwide.
• Timeline: The company expects to report topline data from this registrational trial in the second half of 2027.
• Next Steps: The positive Phase 1 data strengthens confidence as they move into this more advanced, costly, and critical stage of development.

⚖️ The Big Picture: Strengths & Risks

👍 Strengths:

• Clear Mechanism: Data convincingly shows the drug does what it's supposed to do biologically.
• Strong Early Signal: "Super responder" profile in a small group is very encouraging.
• Differentiated Profile: Potential for better safety (no immune depletion) and being redosable could be major advantages.
• Large Market: Type 1 Diabetes affects millions globally with high unmet need for disease-modifying therapies.

⚠️ Risks & Uncertainties:

• Very Early Stage: Phase 1 trials are primarily for safety. Small sample size (n=4 treated) means these efficacy signals are preliminary.
• Future Trial is Key: Success in the larger Phase 2b SAFEGUARD trial is not guaranteed. This is the massive hurdle ahead.
• Development Timeline: Investors must wait until 2H 2027 for the next major data readout.
• Competition: The T1D space has other companies pursuing similar immune-modulating approaches.

🧠 The Analogy

SAB-142 is like a targeted "peacekeeping force" for the pancreas. Instead of bombing the entire immune system (like some broad immunosuppressants do), it specifically deploys mediators to tire out and negotiate with the rebel immune cells (T-cells) that are attacking the body's own insulin factories (beta cells). The early data shows the factories are being protected and can even increase production a little, leading to better daily management for the patient.

🧩 Final Takeaway

SAB Biotherapeutics presented compelling early evidence that their drug SAB-142 successfully modifies the immune system in Type 1 Diabetes patients, leading to preserved insulin production and better blood sugar control. While this builds a strong scientific rationale, everything now hinges on the much larger Phase 2b trial reporting results in late 2027.

CONTACTS: [email protected] (Investor Relations), [email protected] (Media)